Celgene (CELG) Tops Q1 EPS by 12c, Guides FY EPS In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Celgene Reports First Quarter 2019 Operating and Financial Results
April 25, 2019 4:30 PM EDT- Strong double-digit top- and bottom-line growth across portfolio and geographies
- Reaffirming 2019 guidance and 2020 financial targets
- Pipeline execution: fedratinib, ozanimod and luspatercept regulatory applications submitted year-to-date
- Acquisition by Bristol-Myers Squibb approved by shareholders; expected to close in the third quarter of 2019
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) reported net product sales of $4,024 million for the first quarter of 2019, a 14 percent increase from the same period in 2018. Celgene reported first quarter 2019 total... More
